{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:55:11Z","timestamp":1791060911503,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbadis.2026.168172","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:14:30Z","timestamp":1769271270000},"page":"168172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mitigating loss of lean muscle in GLP-1 and dual GLP-1\/GIP agonists: Pipeline opportunities and limitations"],"prefix":"10.1016","volume":"1872","author":[{"given":"Justin","family":"Hierholzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.","family":"Ewida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Salama","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2026.168172_bb0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2026.168172_bb0010","first-page":"S181","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025","volume":"48","author":"Committee, A. D. A. P. P","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbadis.2026.168172_bb0015","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.2337\/dc25-S015","article-title":"15. Management of diabetes in pregnancy: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbadis.2026.168172_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9946924","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management","volume":"2023","author":"Wojtara","year":"2023","journal-title":"Adv. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0025","series-title":"StatPearls","author":"Collins","year":"2025"},{"key":"10.1016\/j.bbadis.2026.168172_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.bbadis.2026.168172_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.4246","article-title":"Drug Shortages Prior to and During the COVID-19 Pandemic","volume":"7","author":"Callaway Kim","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbadis.2026.168172_bb0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0055","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0060","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.apsb.2023.02.020","article-title":"A potentially serious adverse effect of GLP-1 receptor agonists","volume":"13","author":"Lu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbadis.2026.168172_bb0065","article-title":"Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound","volume":"16","author":"Willson","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bbadis.2026.168172_bb0070","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","article-title":"The five-year incidence of progression to osteoarthritis and total joint arthroplasty in patients prescribed glucagon-like peptide 1 receptor agonists","volume":"39","author":"Lavu","year":"2024","journal-title":"J. Arthroplast."},{"key":"10.1016\/j.bbadis.2026.168172_bb0075","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00592-024-02415-w","article-title":"Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system","volume":"62","author":"Xiao","year":"2025","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0080","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2026.168172_bb0085","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","article-title":"Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study","volume":"22","author":"Ueda","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0090","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbadis.2026.168172_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/23259671241297157","article-title":"The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis","volume":"13","author":"Porto","year":"2025","journal-title":"Orthop. J. Sports Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0100","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.cmet.2025.07.004","article-title":"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice","volume":"37","author":"Karasawa","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12777","article-title":"Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?","volume":"81","author":"Luo","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr. Nutr. Rep."},{"issue":"Suppl. 4","key":"10.1016\/j.bbadis.2026.168172_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0125","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.cmet.2025.07.004","article-title":"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice","volume":"37","author":"Karasawa","year":"2025","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0130","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.bbadis.2026.168172_bb0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13370","article-title":"The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: A systematic review and meta-analysis","volume":"23","author":"Nuijten","year":"2022","journal-title":"Obes. Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0145","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/DDDT.S531778","article-title":"Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study","volume":"19","author":"Ren","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbadis.2026.168172_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes. Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0155","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107927","article-title":"Glucagon-like peptide-1 receptor agonists and muscle mass effects","volume":"220","author":"Ceasovschih","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2026.168172_bb0165","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2018-02685","article-title":"Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide","volume":"104","author":"Fonseca","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0170","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0175","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0185","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.bbadis.2026.168172_bb0195","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2026.168172_bb0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5534\/wjmh.200190","article-title":"Rehabilitation Nutrition and Exercise Therapy for Sarcopenia","volume":"40","author":"Kakehi","year":"2022","journal-title":"World J. Mens. Health"},{"key":"10.1016\/j.bbadis.2026.168172_bb0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1743-7075-6-23","article-title":"Effects of a popular exercise and weight loss program on weight loss, body composition, energy expenditure and health in obese women","volume":"6","author":"Kerksick","year":"2009","journal-title":"Nutr. Metab. (Lond.)"},{"key":"10.1016\/j.bbadis.2026.168172_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13442","article-title":"Body composition changes at 12months following different surgical weight loss interventions in adults with obesity: A systematic review and meta-analysis of randomized control trials","volume":"23","author":"Sylivris","year":"2022","journal-title":"Obes. Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-8-36","article-title":"A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program","volume":"8","author":"Frisch","year":"2009","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0230","author":"Inc., V"},{"key":"10.1016\/j.bbadis.2026.168172_bb0235","author":"Scholar Rock, I"},{"key":"10.1016\/j.bbadis.2026.168172_bb0240","author":"Pharmaceuticals, R"},{"key":"10.1016\/j.bbadis.2026.168172_bb0245","author":"Company, E. L. a"},{"key":"10.1016\/j.bbadis.2026.168172_bb0250","author":"Pharmaceuticals, B"},{"key":"10.1016\/j.bbadis.2026.168172_bb0255","author":"Inc., P"},{"key":"10.1016\/j.bbadis.2026.168172_bb0260","author":"Therapeutics, K"},{"key":"10.1016\/j.bbadis.2026.168172_bb0265","author":"Pharmaceuticals, A"},{"key":"10.1016\/j.bbadis.2026.168172_bb0270","author":"Pharmaceuticals, A"},{"key":"10.1016\/j.bbadis.2026.168172_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2023.109306","article-title":"An overview on androgen-mediated actions in skeletal muscle and adipose tissue","volume":"199","author":"Rizk","year":"2023","journal-title":"Steroids"},{"key":"10.1016\/j.bbadis.2026.168172_bb0280","first-page":"232","article-title":"Selective androgen receptor modulators as function promoting therapies","volume":"12","author":"Bhasin","year":"2009","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.bbadis.2026.168172_bb0285","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.bbadis.2026.168172_bb0290","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0295","author":"Administration, U. S. F. a. D"},{"key":"10.1016\/j.bbadis.2026.168172_bb0300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1359-6101(99)00010-6","article-title":"Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action","volume":"10","author":"Saharinen","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2003.10.004","article-title":"The transforming growth factor-beta superfamily of receptors","volume":"15","author":"de Caestecker","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1210\/endrev\/bnab030","article-title":"Myostatin\/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs","volume":"43","author":"Rodgers","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0315","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors","volume":"102","author":"Lee","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2026.168172_bb0320","doi-asserted-by":"crossref","first-page":"23942","DOI":"10.1073\/pnas.2014716117","article-title":"Targeting myostatin\/activin A protects against skeletal muscle and bone loss during spaceflight","volume":"117","author":"Lee","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2026.168172_bb0325","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2026.168172_bb0330","doi-asserted-by":"crossref","first-page":"21037","DOI":"10.1074\/jbc.M110.114959","article-title":"Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb","volume":"285","author":"Sako","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2026.168172_bb0335","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022145","article-title":"TGF-\u03b2 Family Signaling in the Control of Cell Proliferation and Survival","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbadis.2026.168172_bb0340","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1111\/febs.16090","article-title":"Regulation of metabolic homeostasis by the TGF-\u03b2 superfamily receptor ALK7","volume":"289","author":"Ib\u00e1\u00f1ez","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.bbadis.2026.168172_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101830","article-title":"Hepatic Activin E mediates liver-adipose inter-organ communication, suppressing adipose lipolysis in response to elevated serum fatty acids","volume":"78","author":"Griffin","year":"2023","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309967120","article-title":"Activin E-ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice","volume":"120","author":"Adam","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2026.168172_bb0355","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","article-title":"GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates","volume":"16","author":"Mastaitis","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2026.168172_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Pirruccello-Straub","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2026.168172_bb0365","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209151","article-title":"Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3","volume":"102","author":"Crawford","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2026.168172_bb0370","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209151","article-title":"Safety and efficacy of Apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study","volume":"102","author":"Crawford","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2026.168172_bb0375","author":"Rock, S"},{"key":"10.1016\/j.bbadis.2026.168172_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168172_bb0385","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dom.70229","article-title":"Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes","volume":"28","author":"Aimelet","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0390","author":"Pharmaceuticals, N"},{"key":"10.1016\/j.bbadis.2026.168172_bb0395","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbadis.2026.168172_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910273","article-title":"Taldefgrobep Alfa and the phase 3 RESILIENT trial in spinal muscular atrophy","volume":"25","author":"Servais","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2026.168172_bb0405","article-title":"2053-LB: Taldefgrobep Alfa Improves Body Composition as Monotherapy and in Combination with Semaglutide in a DIO Mouse Model","volume":"73","author":"Bechtold","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.bbadis.2026.168172_bb0410","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40120-023-00570-w","article-title":"The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy","volume":"13","author":"Muntoni","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.bbadis.2026.168172_bb0415","doi-asserted-by":"crossref","DOI":"10.2337\/db24-298-OR","article-title":"298-OR: Precision-engineered activin and GDF ligand trap HS235\u2014a novel lean mass\u2013preserving treatment for obesity","volume":"73","author":"Schang","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.bbadis.2026.168172_bb0420","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.017","article-title":"8040 Precision-Engineered Activin and GDF Ligand Trap HS235: A Novel Lean Mass-Preserving Treatment for Obesity","volume":"8","author":"Schang","year":"2024","journal-title":"J. Endocr. Soc."},{"issue":"S125","key":"10.1016\/j.bbadis.2026.168172_bb0425","article-title":"P.191 rker-065, a novel muscle and bone anabolic, increased muscle, grip strength and trabecular bone in a mouse model of Duchenne muscular dystrophy","volume":"32","author":"Nathan","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bbadis.2026.168172_bb0430","author":"Therapeutics, K"},{"key":"10.1016\/j.bbadis.2026.168172_bb0435","doi-asserted-by":"crossref","DOI":"10.2337\/db24-1626-P","article-title":"1626-P: Liver-specific silencing of INHBE with ARO-INHBE, an siRNA therapeutic, for metabolic diseases","volume":"73","author":"NGAI","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.bbadis.2026.168172_bb0440","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03245","article-title":"Adipocyte ALK7 links nutrient overload to catecholamine resistance in obesity","volume":"3","author":"Guo","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.bbadis.2026.168172_bb0445","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161229","article-title":"Targeting activin receptor-like kinase 7 ameliorates adiposity and associated metabolic disorders","volume":"8","author":"Zhao","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbadis.2026.168172_bb0450","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2337\/db18-0857","article-title":"DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes","volume":"68","author":"Emdin","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.bbadis.2026.168172_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/nu10050605","article-title":"Exercise and nutrition strategies to counteract sarcopenic obesity","volume":"10","author":"Trouwborst","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.bbadis.2026.168172_bb0460","doi-asserted-by":"crossref","DOI":"10.1186\/s12937-023-00880-7","article-title":"Benefits and side effects of protein supplementation and exercise in sarcopenic obesity: a scoping review","volume":"22","author":"Cheah","year":"2023","journal-title":"Nutr. J."},{"key":"10.1016\/j.bbadis.2026.168172_bb0465","first-page":"329","article-title":"Effects of very-low-calorie diet on body composition, metabolic state, and genes expression: a randomized double-blind placebo-controlled trial","volume":"21","author":"Merra","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bbadis.2026.168172_bb0470","first-page":"17","article-title":"Reduction of body mass and change in body composition on a very low calorie diet","volume":"17","author":"Hoie","year":"1993","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.bbadis.2026.168172_bb0475","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/nutrit\/nuad007","article-title":"Nutritional and exercise interventions in individuals with sarcopenic obesity around retirement age: a systematic review and meta-analysis","volume":"81","author":"Eglseer","year":"2023","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0480","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/nutrit\/nuad007","article-title":"Nutritional and exercise interventions in individuals with sarcopenic obesity around retirement age: a systematic review and meta-analysis","volume":"81","author":"Eglseer","year":"2023","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.bbadis.2026.168172_bb0485","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.amepre.2022.01.012","article-title":"Obesity Prevalence Among U.S. Adults During the COVID-19 Pandemic","volume":"63","author":"Restrepo","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.bbadis.2026.168172_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.692","article-title":"Higher body mass index is strongly linked to poor outcomes in adult COVID-19 hospitalizations: A National Inpatient Sample Study","volume":"10","author":"Elkhapery","year":"2024","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.bbadis.2026.168172_bb0495","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/PPA.S463354","article-title":"Preference for a novel oral alternative to parenterally administered medications","volume":"18","author":"Myers","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.bbadis.2026.168172_bb0500","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/PPA.S270557","article-title":"Comparative adherence trajectories of oral Fingolimod and injectable disease modifying agents in multiple sclerosis","volume":"14","author":"Earla","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.bbadis.2026.168172_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101931","article-title":"The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis","volume":"85","author":"Talamonti","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bbadis.2026.168172_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107900","article-title":"Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice","volume":"219","author":"Tareq","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2026.168172_bb0515","doi-asserted-by":"crossref","DOI":"10.2337\/db25-1992-LB","article-title":"1992-LB: MYO4, a first-in-class antiobesogenic and muscle preserving small molecule metabolic modulator","volume":"74","author":"Holder","year":"2025","journal-title":"Diabetes"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:25:41Z","timestamp":1791059141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0925443926000207"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168172","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigating loss of lean muscle in GLP-1 and dual GLP-1\/GIP agonists: Pipeline opportunities and limitations","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168172"}}